PENUTUP
A. Kesimpulan
Berdasarkan hasil penelitian Gambaran Tatalaksana COVID-19 pada anak yang Dirawat Inap di RSUD Ulin Banjarmasin, dapat tarik beberapa kesimpulan yaitu :
1. Jenis obat yang digunakan dalam tatalaksana farmakologis pasien anak dengan COVID-19 di RSUD Ulin Banjarmasin adalah antivirus sebanyak (59%) dengan jenis terbanyak adalah Aluvia (47%), antibiotik sebanyak (79%) dengan jumlah terbanyak adalah Azithroycin (59%), kortikosteroid (13%) dengan jenis terbanyak adalah Deksametason (6%) dan Metilprednisolone (6%), Vitamin dan mineral sebesar (93%) dengan jenis terbanyak yang digunakan adalah zinc (78%) , serta pemberian obat-obatan simptomatik lainnya
2. Tatalaksana non-farmakologis pasien anak dengan COVID-19 meliputi pemberian oksigen (18%) menggunakan Nasal Cannula (16%) dan CPAP (9%), pemberian cairan (65%) dengan jenis cairan terbanyak yang digunakan adalah D5 (47%) dan RL (13%), serta pemberian nutrisi melalui oral (13%) dan parenteral (9%)
3. Tatalaksana pasien berdasarkan derajat keparahan penyakit meliputi tatalaksana derajat asimptomatik, ringan, sedang, berat, dan kritis. Pada
55
Universitas Lambung Mangkurat
56
pasien asimptomatik tatalaksana yang dilakukan berupa tatalaksana pemberian antivirus (50%), antibiotic (50%), serta vitamin dan mineral (100%) tanpa diberikan obat-obat simptomatik dan terapi penunjang lainnya. Pasien dengan derajat ringan diberikan tatalaksana utama COVID-19 yaitu pemberian antivirus (69%), antibiotic (54%), kortikosteroid (15%), vitamin dan mineral (100%) disertai tatalaksana suportif seperti pemberian obat-obat simptomatik (77%) dan terapi penunjang lainnya yang disesuaikan dengan gejala klinis yang dimiliki. Tatalaksana pada pasien derajat sedang COVID- 19 diberikan tatalaksana utama COVID-19 yaitu pemberian antivirus (73%), antibiotic (100%), kortikosteroid (9%), vitamin dan mineral (91%) disertai tatalaksana suportif seperti pemberian obat-obat simptomatik (64%) dan terapi penunjang lainnya yaitu pemberian cairan (55%) dan nutrisi (9%). Pada pasien dengan derajat penyakit berat-kritis, pasien dengan distress napas, harus diberikan terapi oksigenasi segera sehingga tatalaksana suportif sangat penting diberikan, selanjutnya pengobatan utama COVID-19 juga diberikan khususnya pemberian antibiotik untuk mencegah sepsis.
B. Saran
Berdasarkan hasil dan pembahasan dari penelitian ini, disarankan :
Perlu dilakukan penelitian yang lebih lanjut untuk melihat hasil dari tatalaksana yang dilakukan pada pasien COVID-19 sehingga mengetahui efektivitas terapi yang dilakukan
Universitas Lambung Mangkurat
DAFTAR PUSTAKA
1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director- general-s-opening-remarks-at-the-media-briefing-on-covid-19 11-march- 2020;
2. Provinsi Kalsel. COVID-19 di Kalimantan. Kalselprov [Internet]. 2020.
Available from: https://corona.kalselprov.go.id/
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–42.
4. IDAI. Panduan Klinis Tata Laksana COVID-19 Pada Anak edisi 2. Ikatan Dokter Anak Indonesia. 2020.
5. Health NI of. COVID-19 Treatment Guides [Internet]. 2021. Available from:
https://www.covid19treatmentguidelines.nih.gov/special-populations/children/
6. Panzeri Carlotti AP de C, de Carvalho WB, Johnston C, Rodriguez IS, Delgado AF. Covid-19 diagnostic and management protocol for pediatric patients.
Clinics. 2020;75:1–5.
7. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc. 2020;323(18):1824–36.
8. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.
Chin Med J (Engl). 2020;133(9):1015–24.
9. Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan dkk. Coronavirus disease 2019: tinjauan literatur terkini. Jurnal Penyakit Dalam Indonesia. 2020;7:45–6.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
2020;395(10223):497–506.
11. Kam KQ, Yung CF, Cui L, Pin Lin RT, Mak TM, Maiwald M, et al. A well infant with coronavirus disease 2019 with high viral load. Clin Infect Dis.
57
2020;71(15):847–9.
12. Sisk B, Cull W, Mitchell Harris J, Rothenburger A, Olson L. National Trends of Cases of COVID-19 in Children Based on US State Health Department Data.
Pediatrics. 2020;146(6).
13. Falahi S, Abdoli A, Kenarkoohi A. Claims and reasons about mild COVID-19 in children. New Microbes New Infect [Internet]. 2021;41:100864. Available from: https://doi.org/10.1016/j.nmni.2021.100864
14. Fang Z, Chun L, Qi-hong F, Hong-bo C, Xue-gong Z, Xi-lin LI, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.
Curr Med Sci. 2020;40(2).
15. Hong H, Wang Y, Chung HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children.
Pediatric Neonatology. 2020;61(2):131–2.
16. Karen M Puopolo, M.D. Ph.D., Mark L Hudak MD, David W Kimberlin, M.D., James Cummings MD. INITIAL GUIDANCE: Management of Infants Born to Mothers with COVID-19. American Academy of Pediatric Committee on Fetus and Newborn, Sect Neonatal Perinatal Medicine and Committee on Infect Disease. 2020;
17. Rastogi D. Quantifying the contribution of obesity to incident childhood asthma: It’s about time. Pediatrics. 2018;142(6):15–7.
18. Rismala Dewi. Tinjauan COVID-19 pada Anak: Infeksi hingga Terapi. J Indones Med Assoc. 2020;70(8):182–9.
19. Aziz R, Graharti R. Clinical Characteristics of Corona Virus Disease (COVID-19 ) In Children Cases In The World. Medula. 2020;10:491–5.
20. Li H, Liu S, Yu X, Tang S, Tang C. Coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Int J Antimicrob Agents.
2020;55(5):105951.
21. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32.
22. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to- person Transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–87.
23. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller
MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002. 5.
24. Umakanthan S, Sahu P, Ranade A V., Bukelo MM, Rao JS, Abrahao- Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753– 8.
25. Balasubramanian S, Neha MR, Anu G, Marion R, Athimalaipet VR.
Coronavirus Disease 2019 (COVID-19) in Children - What We Know So Far and What We Do Not. Indian Pediatrics. 2020;57(5):435–42.
26. Tezer H, Bedir Demirdağ T. Novel coronavirus disease (Covid-19) in children.
Turkish J Med Sci. 2020;50(SI-1):592–603.
27. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3. 2020;36–37
28. PDPI. PERKI. PAPDI. PERDATIN. IDAI. Revisi Protokol Tatalaksana COVID‐19 Juli 2021. 2021;39-50
29. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-1665
30. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020. March 16
31. Parri N, Lenge M, Buonsenso D; Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med. 2020;383(2):187-190.
32. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19:
Focus on Severity and Mortality. Front Public Health. 2020;8:152.
33. Qiu H, Junhua W, Liang H, Yunling L, Qifa S, Dong C. Clinical and Epidemiological features of 36 Children with Coronavirus Disease 2019 (COVID019) in Zhejiang,China : an observational cohort study. The Lancet.
2020;20 :689-696.
34. Saheb Sharif-Askari N , Saheb Sharif-Askari F , Alabed M , et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther Methods Clin Dev 2020;18:1–6
35. Kashiouris MG, L’Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler
AA. The Emerging Role of Vitamin C as a Treatment for Sepsis. Nutrients.
2020; 12(2):292
36. c19zinc.com (2021). Zinc studies. c19zinc.com/
37. A. Israel, A.A. Schäffer, A. Cicurel, I. Feldhamer, A. Tal, K. Cheng, et al.
Identification of drugs associated with reduced severity of COVID-19: a case–
control study in a large population eLife, 10 (2021), p. e6816
38. A.Z. Velija, T.D. Al Selenium, zinc, and vitamin D supplementation affect the clinical course of COVID-19 infection in Hashimoto's thyroiditis. In endocrine abstracts Bioscientifica, 73 (2021)
39. Venturini, E., Montagnani, C., Garazzino, S. et al. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease.
Ital J Pediatr 46, 139 (2020)
40. Chadwick EG, Pinto J, Yogev R, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J. 2009;28(3):215-219.
41. Kang C.K., Seong M.W., Choi S.J., Kim T.S., Choe P.G., Song S.H. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. Korean J Intern Med.2020;35:728-787
42. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA.
2020;323(15):1488–1494.
43. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14 (1):58–60.
44. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93 (7):449–63.
45. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395
46. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254.
47. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering. 2020. doi:
10. 1016/j.eng.2020.03.007
48. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al.
Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 90 2017;43(3):304–77.
49. Poschet J, Perkett E, Timmins G, Deretic V. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells.bioRxiv. 2020;
50. E. J. T. Aguila, I. H. Y. Cua, J. A. C. Fontanilla, V. L. M. Yabut, and M. F. P.
Causing, “Gastrointestinal manifestations of COVID-19: impact on nutrition practices,” Nutrition in Clinical Practice, vol. 35, no. 5, pp. 800–805, 2020.
51. R. Hashem and C. Weissman, “Renal dysfunction and fluid and electrolyte disturbances,” Current Opinion in Critical Care, vol. 17, no. 4, pp. 390–395, 2011.
52. Guidance For Nutrition Management Of 19 For Health Workers In Covid-19 Treatement And Isolation Centres. 2020
53. Instiaty, Darmayani IGAAPS, Marzuki JE, et al.: Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Med J Indones. 2020; 29(3) 54. Z. Hu, C. Song, C. Xu, G. Jin, Y. Chen, X. Xu, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China Sci China Life Sci, 63 (5) (2020), pp. 706-711
LAMPIRAN
Lampiran 1. Formulir Pengumpulan data Penelitian
Universitas Lambung Mangkurat
Lampiran 2. Tabulasi dan data hasil penelitian
No No RM Usia JK
(P/
L)
Derajat
Ruang Rawat
Tatalaksana
Farmakologis Non-farmakologis
AV AB Kor Vit OL 02 Cr N
1 1- 47- 27- 74
1 7
P R Mawar 2b Favipira vir
Azithromy cin
_ Vit D
Curcum a Zinc
VIP Albumin L bio
_ RL _
Becomz et 2 1-
45- 85- 85
1 7
P R Mawar 2a Oseltam
ivir
Azithromy cin
_ Vit C
Vit E Zinc As Folat
Paracetam ol
_ Ds 1/2 NS _
3 1- 44- 00- 08
1 5
L S Mawar 5b aluvia (Lopinav ir + Ritonavi
Azithromy cin
_ Vit C
Vit E As.
Folat
_ _ _ _
r 4 1-
47- 24- 84
0 bl n
L K Inrit
Mawar
_ Ampicilin
Gentamici n
Azithromy
_ Zink
Vit K Supraly cin
Interlac O2 NC O2 CPAP
TPN OG
T
67
cin Ceftrazidi me
5 1- 46- 21- 10
1 7
P S Mawar 2b) Aluvia Azithromy cin Ceftriaxon e
_ Zink
Vit C Vid D
Omeprazol e
Ondasetro n
_ Ds 1/2 NS _
Meropene Paracetam
m ol
Ambroxol Salbutamo l
Oralit Loratadine Lacto B Loperamid e
Betadine kumur 6 1-
45- 85- 92
1 0
L S Mawar 5b Aluvia Azithromy cin
_ Vit C
Vit E Zinc As.
_ _ _ _
Folat 7 1-
46- 76- 31
2 P R Mawar 2b) Aluvia _ _ Vit C
Vit B Zinc
_ _ _ _
8 0- 86- 56- 91
1 2
L S Mawar 2b Aluvia Azithromy cin Ceftriaxon e
Metilpredniso lone
Vit C Vit E Vit K As.
Folat
_ _ IVFD KAEN
Ds 1/2 NS
_
9 1- 46- 00- 59
0 bl n
P S Inrit
Mawar2b
_ Ampicilin
Gentamici n
Azithromy cin
_ Vit C
Vit K ZinC Supraly cin Enystin Interlac
Prebiotik _ _ OG
T
1 0
1- 46- 13- 17
0 bl n
P K Inrit
Mawar 2b
_ Ampicilin
Gentamici n
Azithromy cin
_ Vit C
Vit K ZinC Supraly cin Interlac
_ o2 NC
O2 CPAP
(tpn) Inf D10 + Ca glukosa
OG T
1 1
1- 47- 27- 77
0 bl n
P B Inrit
ICU/NICU
_ Ampicilin
Gentamicn Azithromy cin
_ Vit K
Zinc Interlac
_ O2
CPAP
TPN AA (Amonisteril/
Asam Amino) 6% )
inf d12 5% + ca glu)
OG T
1 2
0- 88- 40- 98
1 7
L S Mawar 3b Favipira vir
Azithromy cin Ceftriaxon e
_ Vit D
Vit C Becomz et
L bio Ambroxol Salbutamo l
_ _ _
1 3
1- 47- 09- 07
1 5
P S Mawar 3b _ Azithromy
cin
_ Vit D
Vit C Becomz et
Ambroxol Salbutamo l
Loratadine
_ _ _
1 4
1- 44- 70- 14
3 P R Mawar 2b _ _ _ Vit C
Vit D Zinc
Paracetam ol
1 5
1- 15- 29- 25
1 4
P A Mawar 5b _ _ _ Vit C
Vit D Zinc
_ _ _ _
1 6
1- 43- 45- 25
9 L R Mawar 5b _ _ Metilpredniso
lone
Vit C Vit D Zinc
_ _ D5% + ½ NS
infus Wida
_
1 7
146 516 0
3 L R Mawar 2b Aluvia _ _ Vit C
Vit D Zinc
Lacto B Oralit Ondansetr on
Ca Lactat
IVF RL I IVFD d5 ½ NS IVFD KAEN 3B
_
1 8
141 147 8
1 2
L R Mawar 2b Aluvia Azithromy cin
_ Vit C
Zinc
_ _ IVFD D5 1/2 NS _
1 9
146 095 1
1 L S Mawar 5b Aluvia Azithromy cin Ceftriaxon e
_ _ _ _ IVFD D5 1/2 NS _
2 0
144 564 3
3 L S Mawar 2b Aluvia Ceftriaxon e
_ Vit C
Vit D Zinc
Lacto B Oralit Paracetam ol
Diazepam
_ IVFD D5 1/2 NS _
2 1
146 099 7
9 bl n
L K Mawar
PICU
_ Ceftriaxon
e
_ _ Ondancetr
on
Paracetam ol
epinefrin o2 2LPM (kateter Nasofar ing / Nasal Canul??
)
IVFD RD5 200 cc
_
2 2
144 938 7
7 bl n
L B Mawar 5b Aluvia Ceftriaxon e
Gentamici n
Azithromy cin
Dexamethaso ne
ZinC L bio Phenobarb ital
Paracetam ol
Diazepam Ambroxol Salbutamo l
O2 NC D5 1/4 NS NG T
2 3
146 262 9
1 6
P R Mawar lt 1 aluvia Azithromy cin Ceftriaxon e
_ Vit C
Vit D ZinC
Loratadine _ IVFD NACL _
2 4
147 067 2
1 P B Mawar
PICU
_ Azithromy
cin Ceftriaxon e
cefixime
_ Vit C
Vit D Vit K Becomz et ZinC Supraly sin
Paracetam ol
Salbutamo l
Ambroxol L bio asam traneksam at
Cetirizine
02 NC IVFD D5 ¼ NS VFD
D10%+KCL+Na Cl+Ca glukonas
_
2 5
145 906 8
9 L A Mawar Aluvia Azithromy
cin Ceftriaxon e
Cotrimoxa zole
_ Vit C
Vit E Curvit ZinC
_ _ _ _
2 6
146 225 3
1 4
P R Anggrek lt 2
Aluvia Azithromy cin Ceftriaxon e
_ Vit C
Vit D ZinC
Ketorolac _ RL
D5
_
2 7
146 643
7 L R Mawar 2b Aluvia _ _ Vit C
Vit B Zinc
Lacbon Omeprazol e
Ondansetr on
Cetirizine
_ IVFD D5 1/2 NS _
2 8
146 832 8
3 bl n
P S Mawar 2b _ Metronida
zole
_ Vit D
Vit K ZinC
Oralit Lacto B
_ IVFD KAEN
Ds
_
2 9
1- 45- 91- 63
1 1
P R Mawar 2b _ _ _ Vit C As
Traneksam at
Antasida Omeprazol e
_ IVFD Nacl 0.9% _
3 0
146 832 8
1 7
P R Mawar 2b Favipira vir
Meropene m
Fluconazol e
metronida zole Ceftiaxone cefixime
Dexamethaso ne
Vit B Vit C ZinC Becomz et Curvit Vit D
Lacto B Ondansetr on
Omeprazol e
salbutamol Ambroxol Kodein Paracetam ol
cetirizin
_ IVFD D5 1/2 NS _
3 1
146 288 1
1 7
P R anggrek lt 1
_ Ceftriaxon
e
_ Vit D
Vit C Curvit
Omeprazol e
Ondansent ron Cetirizine Sucralfat
_ IVFD RL _
3 2
146 603 7
8 bl n
P S Mawar 2b Aluvia Ceftriaxon e
cefixime
_ Vit D
Vit C ZinC
Lacto B Paracetam ol
cetirizine
_ IVFD D5 _
Keterangan : RM= Rekam Medis L= Laki-laki
P= Perempuan Av= Antivirus Ab= Antibiotik Kor= Kortikosteroid Vit= Vitamin
OL= Obat-obat Lain Cr= Cairan
N= Nutrisi